Comparison of Mono therapy with' piperacillin/tazobactam 'and multiple drugs therapy for the treatment of perforated appendix in children.

Evaluate the effectiveness of mono therapy with piperacillin/tazobactam and multiple drugs therapy for the treatment of perforated appendix in children: ( from 4 years till 13 years) A randomised control trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12624001312538

Acronym

none

Enrollment

Registered

2024-10-29

Start date

2023-12-25

Completion date

2024-06-24

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

comparison of mono therapy with piperacillin/tazobactam and multiple drugs therapy for the treatment of perforated appendix in children: A randomized control trial. monotherapy is as efficient as multi drug therapy saving hospital resources

Interventions

Research was conducted in Mayo Hospital Lahore Pediatric Surgery Ward Two groups were made Group A received monotherapy with piperacillin / tazobactam 100 mg/ kg 8 hourly intravenous for 7 days Group B received multi drug therapy which included Meropenem 20 mg/kg 8 hourly intravenous and Metronidazole 7.5mg / kg 8 hourly intravenous for 7 days. These drugs started postoperative one day after surgery

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver)

Eligibility

Sex/Gender

All

Age

4 Years to 13 Years

Healthy volunteers

Inclusion criteria

Patient having perforated appendix Age from 4 to 13 years Given informed consent Included in this study

Exclusion criteria